Estranes

Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids

Retrieved on: 
Tuesday, July 20, 2021
Drugs, Chemical compounds, Chemistry, Combination drugs, Estrogens, Estranes, Prolactin releasers, GnRH antagonists, Relugolix/estradiol/norethisterone acetate, Uterine fibroid, Relugolix, Estradiol

With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.

Key Points: 
  • With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.
  • Todays approval of RYEQO, the first and only once-daily long-term treatment for women with uterine fibroids in Europe, marks a major milestone in expanding non-invasive treatment options for this common and potentially debilitating disease, said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
  • Through our partnership with Gedeon Richter, we look forward to supporting even more women suffering from uterine fibroids.
  • RYEQO (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Global Uterine Fibroids Clinical Landscape Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Pharmaceutical, Health, Clinical trials, Hormones, Endocrine system, Selective progesterone receptor modulators, Diketones, Progestogens, Estranes, GnRH antagonists, Uterine fibroid, Ulipristal acetate, Leuprorelin, Elagolix/estradiol/norethindrone acetate, Progesterone

This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • Lupron, Orgovyx, and ORIAHNN, which target gonadotropin-releasing hormone receptor, and ulipristal acetate, which targets progesterone receptor, are the only approved drugs for uterine fibroids.
  • The largest proportion of industry-sponsored drugs in active clinical development for uterine fibroids are in Phase III, with one drug in the NDA/BLA phase.
  • Repros Therapeutics has the highest number of completed clinical trials for uterine fibroids, with 17 trials.

Global Transdermal Skin Patches Market Report 2021-2026: Players Gaining Attention Include Teva Pharmaceuticals, Novartis AG, Teikoku Pharma, Mylan, 3M - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Surgery, Health, Sex hormones, Drugs, Organic compounds, Estranes, Hormonal contraception, Hepatotoxins, Prolactin releasers, Phenols, Levonorgestrel, Contraceptive patch, Estradiol, Ethinylestradiol

For instance, in February 2020, the US FDA approved the Contraceptive Patch known has Twirla (levonorgestrel and Ethinylestradiol) Transdermal System, it is a New Weekly Contraceptive Patch from the company, Agile Therapeutics Inc..

Key Points: 
  • For instance, in February 2020, the US FDA approved the Contraceptive Patch known has Twirla (levonorgestrel and Ethinylestradiol) Transdermal System, it is a New Weekly Contraceptive Patch from the company, Agile Therapeutics Inc..
  • Smoking damages lung function and makes it harder for the body to fight off coronaviruses and other infections.
  • According to the World Health Organization, 8 million people die each year as a result of smoking.
  • About 16 million Americans live with a smoking-related disease.

Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 12, 2021
Sex hormones, Drugs, Organic compounds, Estranes, Hormonal contraception, Hepatotoxins, Prolactin releasers, Phenols, XC2, Levonorgestrel, Estradiol, Ethinylestradiol

b"PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\xe2\x80\x99s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET.\nThe fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here: https://event.on24.com/wcc/r/3173531/F391B23E756682EFEFE4952267784F45\nThe webcast will be archived on the Agile Therapeutics website for 30 days following the event.\nAgile Therapeutics\xc2\xa0is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today\xe2\x80\x99s women.\xc2\xa0Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.\xc2\xa0Our initial product, Twirla\xc2\xae, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive.

Key Points: 
  • b"PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\xe2\x80\x99s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET.\nThe fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here: https://event.on24.com/wcc/r/3173531/F391B23E756682EFEFE4952267784F45\nThe webcast will be archived on the Agile Therapeutics website for 30 days following the event.\nAgile Therapeutics\xc2\xa0is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today\xe2\x80\x99s women.\xc2\xa0Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.\xc2\xa0Our initial product, Twirla\xc2\xae, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive.
  • Twirla is based on our proprietary transdermal patch technology, called Skinfusion\xc2\xae, which is designed to allow drug delivery through the skin.
  • For more information, please visit the company website at www.agiletherapeutics.com .
  • The Company may occasionally disseminate material, nonpublic information on the Company\xe2\x80\x99s website.\n"

Global $4+ Billion SERD Therapeutics Market to 2030: Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859

Retrieved on: 
Wednesday, April 28, 2021
Antiestrogens, Drugs, Selective estrogen receptor degraders, Companies, Estranes, Organofluorides, Fulvestrant, Health care, AstraZeneca

Rise in government and private funding for improved safety and outcomes provided by SERD therapy are additional factors propelling the growth.\nBased on region, North America is the leading contributor to the SERD therapeutics market in terms of revenue.

Key Points: 
  • Rise in government and private funding for improved safety and outcomes provided by SERD therapy are additional factors propelling the growth.\nBased on region, North America is the leading contributor to the SERD therapeutics market in terms of revenue.
  • The growing breast cancer incidence, relapse from existing endocrine therapies, and the substantial research and development made in the field are consequentially promoting the growth of the North America SERD therapeutics market.
  • The market dominance of these companies can be attributed to cost-effective generic fulvestrant availability in the market.\nAs of 2018, AstraZeneca Plc was the only company to offer SERD therapy in the global SERD therapeutics market.
  • With the pipeline of SERD therapeutics, the market is expected to augment tremendously.

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive

Retrieved on: 
Friday, April 16, 2021
Sex hormones, Drugs, Hormones, Hepatotoxins, Progestogens, Hormonal contraception, Prolactin releasers, Estranes, Birth control, Medroxyprogesterone acetate, Estrogen, Emergency contraception

"\nNearly 10 million American women use short-acting combination contraceptives (estrogen and progestin).

Key Points: 
  • "\nNearly 10 million American women use short-acting combination contraceptives (estrogen and progestin).
  • It has more selective activity in tissues, focusing on those needed to support contraceptive efficacy, cycle control and other beneficial effects of estrogen.
  • According to phase 3 study findings, NEXTSTELLIS demonstrated contraceptive efficacy across all subgroups by age, BMI1 and prior hormonal contraception use.
  • The company has an extensive Women\'s Health portfolio focused on contraceptives, including its flagship birth control product, NEXTSTELLIS.

Daré Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-Oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Symptoms and Genitourinary Syndrome Associated with Menopau

Retrieved on: 
Monday, March 22, 2021
Steroids, Organ systems, Hormones, Prolactin releasers, Hepatotoxins, Estranes, Estrogens, Phenols, Hot flash, Progesterone, Menopause, Estradiol

DARE-HRT1 is a novel intravaginal ring (IVR) designed to deliver bio-identical 17-estradiol and bio-identical progesterone continuously over a 28-day period.

Key Points: 
  • DARE-HRT1 is a novel intravaginal ring (IVR) designed to deliver bio-identical 17-estradiol and bio-identical progesterone continuously over a 28-day period.
  • It is being developed for the treatment of vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause as part of a hormone therapy regimen.
  • The randomized Phase 1 study is designed to evaluate the pharmacokinetics (PK) of DARE-HRT1 in approximately 30 healthy, post-menopausal women.
  • The primary objective of the study is to describe the PK parameters of two different dose combinations over 28 days.

Global Selective Estrogen Receptor Degrader SERD Inhibitors Drug Market Clinical Trials Report 2025

Retrieved on: 
Monday, March 15, 2021
Hormones, Endocrine system, Organ systems, Antiestrogens, Hepatotoxins, Prolactin releasers, Estranes, Progonadotropins, Selective estrogen receptor degrader, Estrogen receptor, Estrogen, Breast cancer

Selective estrogen receptor degrader therapy market has led to the overall fragmentation of the market towards the applications of the market that it has distributed in such short period of time.

Key Points: 
  • Selective estrogen receptor degrader therapy market has led to the overall fragmentation of the market towards the applications of the market that it has distributed in such short period of time.
  • The overall combined shift led by the selective estrogen receptor degrader therapy market perhaps is representing a major breakthrough that has pushed the patients to receive real treatment for their local or advanced breast cancer.
  • As per "Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" report findings, it is estimated that the market is capable of offering advancements in the medical treatment with its ability to target the major receptors that are however important for regulating the growth of the cancer cells.
  • The current selective estrogen receptor degrader therapy market landscape is estimated to grow even more stronger and cause a steep growth in market size in the next few years.

Global Selective Estrogen Receptor Degrader SERD Inhibitors Drug Market Clinical Trials Report 2025

Retrieved on: 
Monday, March 15, 2021
Hormones, Endocrine system, Organ systems, Antiestrogens, Hepatotoxins, Prolactin releasers, Estranes, Progonadotropins, Selective estrogen receptor degrader, Estrogen receptor, Estrogen, Breast cancer

Selective estrogen receptor degrader therapy market has led to the overall fragmentation of the market towards the applications of the market that it has distributed in such short period of time.

Key Points: 
  • Selective estrogen receptor degrader therapy market has led to the overall fragmentation of the market towards the applications of the market that it has distributed in such short period of time.
  • The overall combined shift led by the selective estrogen receptor degrader therapy market perhaps is representing a major breakthrough that has pushed the patients to receive real treatment for their local or advanced breast cancer.
  • As per "Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" report findings, it is estimated that the market is capable of offering advancements in the medical treatment with its ability to target the major receptors that are however important for regulating the growth of the cancer cells.
  • The current selective estrogen receptor degrader therapy market landscape is estimated to grow even more stronger and cause a steep growth in market size in the next few years.

Mithra and Searchlight Pharma Announce Nextstellis® Approval in Canada

Retrieved on: 
Monday, March 8, 2021
Organic compounds, Chemical compounds, Sex hormones, Hormonal contraception, Estranes, Estrogens, Phenols, Polyols, Estetrol, Drospirenone, DRSP, Estetrol/drospirenone

Developed by Mithra, Nextstellis is composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP) in a 24/4 dosing regimen.

Key Points: 
  • Developed by Mithra, Nextstellis is composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP) in a 24/4 dosing regimen.
  • "For this reason, the approval of an additional novel contraceptive option in Canada is incredibly welcome.
  • The approval in Canada is the first marketing authorization for Nextstellis in any jurisdiction, anywhere in the world.
  • "We are excited that Canada is the first market globally to approve Nextstellis, and that Searchlight Pharma can now move forward with its commercial launch and making this new contraceptive option available to Canadian women," said Mark Nawacki, President & CEO of Searchlight Pharma.